LANN-study: Lantus, Amaryl, Novorapid, Novomix Study
NCT00151697
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
150
Enrollment
OTHER
Sponsor class
Conditions
Diabetes Mellitus Type II
Interventions
DRUG:
Novomix 30
DRUG:
Novorapid and Amaryl
DRUG:
Lantus
Sponsor
Rijnstate Hospital